neurogene.com (NGNE) - Long-Term Liabilities to Capital

Neurogene Inc. (NGNE) is establishing a cutting-edge environment for brain gene restoration, where the EXACT method provides precision protein regulation for the treatment of orphan pathologies. However, the business relies on fragile Asian supply chains and faces patent conflicts, which impact the metric represented by 0.02. With minimal environmental impact and strict biocontrol, the price trajectory of NGNE shares shown below reflects the asset's dynamics.

This ratio measures the proportion of long-term liabilities relative to equity, determining the degree of financial leverage and the company's dependence on external borrowing for long-term planning. For Neurogene Inc. (NGNE), which invests in costly gene therapy developments, assessing the long-term debt-to-equity ratio provides insight into the sustainability of research funding until the commercialization of patents and the achievement of superprofits.